Teriparatide

Teriparatide is a recombinant form of the first 34 amino acids (the 1-34 fragment) of human parathyroid hormone (PTH). Unlike many peptides discussed in wellness or experimental settings, it is a fully approved prescription medicine, marketed under the brand name Forteo and available in biosimilar and generic forms in some regions. It belongs to the "anabolic" or bone-building category of osteoporosis therapies, distinct from the "antiresorptive" drugs that primarily slow bone loss.

The 1-34 fragment retains the biologically active portion of full-length PTH. Because it is a genuine approved drug rather than a research-only compound, its use is defined by regulatory labeling and clinical supervision.

Teriparatide acts on PTH receptors on bone-forming cells. Its defining feature is that the biological outcome depends on the pattern of exposure:

• Intermittent exposure preferentially stimulates osteoblast activity, favoring new bone formation

• Continuous elevation of PTH, by contrast, tends to drive net bone breakdown, as seen in hyperparathyroidism

This "same molecule, opposite effect" relationship is central to how teriparatide works. The anabolic benefit is tied to short, pulsed exposure rather than sustained high levels, which is why the pattern of administration matters as much as the molecule itself.

In regulated medical practice, teriparatide has been approved (depending on jurisdiction) for osteoporosis in people at high risk of fracture, including postmenopausal osteoporosis, osteoporosis in men, and glucocorticoid-induced osteoporosis. It is generally positioned for higher-risk situations rather than as a first-line option for everyone.

It should not be confused with the peptides marketed in body-composition or performance contexts; teriparatide is a bone-directed anabolic agent with a specific, evidence-based role. Any use should be guided by a qualified clinician and aligned with local regulations and product labeling.

Teriparatide is a rare case among injectable peptides on this site: it is a peptide hormone, it is anabolic, and it is nevertheless not prohibited. Neither teriparatide nor any parathyroid hormone analogue is named on the WADA Prohibited List, and S2's peptide hormone sub-sections are enumerated categories — erythropoietins, testosterone-stimulating peptides, corticotrophins, growth hormone and its releasing factors, and named growth factors — none of which includes PTH signalling. The S0 catch-all does not apply either, because teriparatide is an approved medicine with FDA and EMA labels.

The reason is mechanistic rather than an oversight. PTH(1-34) is "anabolic" in the narrow skeletal sense: intermittent dosing shifts bone remodelling toward formation. It does not increase lean mass, oxygen-carrying capacity, or recovery capacity, which are the properties S1-S5 are built around.

Two caveats that are real rather than boilerplate. First, teriparatide's original US label carried a boxed warning about osteosarcoma risk observed in rats, and the drug is not casually prescribed — anti-doping status is not the binding constraint on its use. Second, the injectable route is unaffected by the Prohibited List, but M2.2 separately caps intravenous infusions and injections at 100 mL per 12-hour period; a subcutaneous teriparatide pen is nowhere near that volume and is not implicated.

Commonly described effects include transient dizziness or a drop in blood pressure shortly after administration, leg cramps, nausea, headache, and injection-site reactions. Changes in calcium levels are also monitored because PTH influences calcium handling.

Historically, teriparatide labeling carried a boxed warning based on a rodent study in which some animals developed osteosarcoma (a bone cancer) with high, prolonged exposure. This finding shaped early duration limits and prescribing cautions; the human relevance has been the subject of extended follow-up research, and labeling in some regions has since been revised. Contraindications, duration, and monitoring should be determined by a prescribing clinician.

Teriparatide is administered by subcutaneous injection, and its anabolic benefit depends on brief, pulsed exposure rather than sustained elevation. Historically, total treatment duration has also been a defined consideration in labeling.

This page intentionally avoids specific numbers, schedules, or protocols. The amount, frequency, and overall course are governed by the approved product's labeling and by the prescribing clinician. What is worth understanding conceptually is why exposure pattern, not just quantity, determines whether PTH signaling builds or removes bone.

The approved medicine is typically supplied as a multi-dose prefilled subcutaneous pen. In clinical practice, anabolic therapy is often discussed in sequence with antiresorptive agents, since the durability of gains can depend on follow-on treatment after an anabolic course.

Any structural or catalog listings are organizational and are not endorsements of specific combinations, sourcing, or use cases. Teriparatide's role is defined by osteoporosis treatment frameworks rather than by general peptide catalogs.

Randomized controlled trials have evaluated teriparatide's effects on bone mineral density and fracture risk in osteoporosis, and it is one of the better-studied anabolic bone agents. Research has also compared anabolic and antiresorptive sequencing and examined its use in specific populations such as glucocorticoid-induced osteoporosis.

Because the evidence base evolves, this is a high-level snapshot rather than a comprehensive or permanently current review. Clinical and personal decisions should rely on up-to-date primary literature, current labeling, and trusted guidelines.

For deeper dives on this peptide, see:

• Teriparatide benefits and areas of interest
• Teriparatide side effects and safety context
• Teriparatide dosing concepts (educational)
• Teriparatide research and evidence overview

Why does intermittent PTH build bone while continuous PTH removes it? The approved labeling states the principle directly: the skeletal effects of teriparatide depend on the pattern of systemic exposure. Once-daily administration stimulates new bone formation on trabecular and cortical surfaces by preferentially stimulating osteoblastic over osteoclastic activity, whereas a continuous excess of endogenous PTH, as in hyperparathyroidism, may be detrimental to the skeleton because resorption may be stimulated more than formation (Forteo prescribing information). Mechanistic work attributes the anabolic side largely to an increase in osteoblast number — including delayed osteoblast apoptosis and signaling through IGF-I, FGF-2, and Wnt pathways — so that bone formation outpaces the resorption occurring alongside it (Jilka, Bone 2007).

How is anabolic therapy different from antiresorptive drugs? Antiresorptive agents such as bisphosphonates slow the rate at which bone is removed, preserving what is already there. Anabolic agents such as teriparatide stimulate new bone formation instead. The VERO trial compared them directly in 680 postmenopausal women per arm with severe osteoporosis: over 24 months, new vertebral fractures occurred in 5.4% on teriparatide versus 12.0% on risedronate (risk ratio 0.44, 95% CI 0.29–0.68), and clinical fractures in 4.8% versus 9.8% (Kendler et al., Lancet 2018). The two categories are often discussed in sequence, because gains made during an anabolic course depend on what follows it.

What did the rodent osteosarcoma finding actually establish? In a two-year study, Fischer 344 rats given daily PTH(1-34) developed osteosarcoma at rates that rose with dose; the investigators concluded the findings reflected near-lifetime dosing in a rapidly modeling rat skeleton and were not predictive of increased bone cancer risk in skeletally mature adults treated for osteoporosis (Vahle et al., Toxicol Pathol 2002). That finding drove a boxed warning and a lifetime treatment cap on the original US label. A 15-year US postmarketing surveillance study then found no signal in humans: among 1,173 interviewed adults with osteosarcoma, three reported prior teriparatide use, against 4.17 expected (standardized incidence ratio 0.72, 90% CI 0.20–1.86) (Gilsenan et al., J Bone Miner Res 2021).

Does the current label still carry a boxed warning? No. The current US Forteo label has no boxed warning; osteosarcoma now appears under Warnings and Precautions, framed as avoiding use in people at increased risk — such as those with open epiphyses, Paget's disease or other metabolic bone disease, bone metastases or a history of skeletal malignancy, prior skeletal radiation, or hereditary predisposition to osteosarcoma (Forteo prescribing information). The change reflects accumulated human surveillance data rather than a reinterpretation of the rat study.

What is Forteo approved for, and for how long? The US label lists three indications: postmenopausal women with osteoporosis at high risk for fracture, increasing bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture, and men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture — each including people who have failed or cannot tolerate other osteoporosis therapy. On duration, the label states that use beyond two years during a patient's lifetime should only be considered if the person remains at, or has returned to, high fracture risk (Forteo prescribing information).

How strong is the fracture evidence? The pivotal trial randomized 1,637 postmenopausal women with prior vertebral fractures to PTH(1-34) or placebo for a median of 21 months. New vertebral fractures occurred in 5% of the 20 µg group and 4% of the 40 µg group versus 14% on placebo, and non-vertebral fragility fractures in 3% of each treated group versus 6% on placebo; lumbar spine bone mineral density rose 9 and 13 percentage points more than placebo (Neer et al., NEJM 2001). The 20 µg dose became the approved one.

Is teriparatide a "peptide" in the sense the rest of this site means? Only in the chemical sense. It is a 34-amino-acid recombinant fragment of human parathyroid hormone, so it is structurally a peptide — but unlike most compounds catalogued alongside it, it is an approved prescription medicine with an FDA label, defined indications, contraindications, and postmarketing surveillance behind it. Grouping it with gray-market research peptides obscures that difference, and none of the fracture data above describes unapproved material.